Recent progress in plasmonic nanoparticle‐based biomarker detection and cytometry for the study of central nervous system disorders

Peng, Fei; Jeong, Seong‐Min; Ho, Alexander; Evans, Conor L.

doi:10.1002/cyto.a.24489

Cited by 7 publications

(4 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ubiquitin-C-terminal hydrolase-L1 (UCH-L1) plasma limits have been found to be significantly higher in TBI patients than in healthy people, implying that UCH-L1 could be a viable diagnostic marker for the situation [42]. An innovative technique based on the surface plasmon resonance of Au NPs has recently been shown to successfully and swiftly identify the biomarker UCH-L1 in TBI patients with 100% sensitivity and specificity [43].…”

Section: Biomarker Detectionmentioning

confidence: 99%

Recent Advancements in Phyto Component Based Nanocarriers for Improved Treatment of Brain Disorders

Satapathy¹,

Pattnaik²,

Biswal³

et al. 2023

Drug Repurposing - Advances, Scopes and Opportunities in Drug Discovery

View full text Add to dashboard Cite

Effective treatment of brain disorders remains a tough task in medical science. Age-old brain disorders like Parkinson’s (PD) and Alzheimer’s (AD) are yet to be managed effectively in spite of fabulous scientific progress over the last decades. Presently available treatment strategies have been found insufficient to tackle the out bursting cases of AD and PD. Indeed, presence of blood-brain barrier (BBB) highly hijacks success of conventional drug therapy. In this regard, phyto bioactive components delivered through nanocarrier (NCs) systems hold ray of hope in improving treatment benefits in brain disorders. Several NCs including polymeric nanoparticles, nanoliposomes, micelles, dendrimers have now being heavily researched to effectively deliver the phyto active components to brain tissue. NCs owing to their structural and physiological uniqueness have now been evolved with great potential for the treatment of brain disorders. Functionalization of brain specific ligands on the surface of NCs further makes them target specific, which might significantly improve bioavailability or reduce the off-target adverse effects. This chapter primarily focuses on recent advancements in phyto component loaded NCs employed for the treatment of brain disorders. The chapter especially covers existing impediments of phyto component based NCs for Parkinson and Alzheimer’s disease.

show abstract

Section: Biomarker Detectionmentioning

confidence: 99%

Recent Advancements in Phyto Component Based Nanocarriers for Improved Treatment of Brain Disorders

Satapathy¹,

Pattnaik²,

Biswal³

et al. 2023

Drug Repurposing - Advances, Scopes and Opportunities in Drug Discovery

View full text Add to dashboard Cite

show abstract

“…However, the complexities of the CNS provide significant hurdles to the analysis done by this equipment on many biomarkers. [23] Essentially, bio-sensing equipment are designed to convert biological or chemical events into countable signals that provide quantitative and/or qualitative information about the sought -after biomarkers. [24] Biosensors are normally comprised of the detector, which confirms the impetus; the transducer, which converts the impetus to a valuable consequence; and the signal handling technique, which displays the results in a suitable and legible style, [10] as illustrated in Figure 2.…”

Section: Recent Developments In Widespread Neurological Disordersmentioning

confidence: 99%

Recent Progress on Biosensors for the Early Detection of Neurological Disorders.

Chougale

Vedante

Kulkarni³

et al. 2022

ChemistrySelect

View full text Add to dashboard Cite

Neurological disorders are a point of attraction these days due to their physical, mental, and genetic threat to human beings. The researchers are refining the therapeutics and striving to eradicate the life-threatening burden of chronic diseases by upsurging and proposing advanced instrumentation. There are a number of neurological diseases that cause alterations in the genetic sequences due to pathogenic or self-negligence. According to the WHO, stroke, septicemia, PD, epilepsy, and MS are found to be the deadliest and most invading among millions of people. Various diagnostic methods are employed for monitoring these disorders in the human body at an early stage, in process of cure. The current review highlights the strengths of several advanced detection devices, such as biosensors to identify and quantify biomarkers, some sensing gadgets, and other genetic tactics or innovations to ameliorate traditional protocols. Furthermore, the meticulous description of ongoing experiments with the help of relevant case studies of neurodegenerative disorders supports the impact and vitality of advanced equipment. Further, the necessity of biosensors in distinct disorders to aid in an early diagnosis, and the influence of nano-based materials in preparation is emphasized. Finally, several issues that should be addressed in upcoming decades with the steep rise in analytical technology have been discussed.

show abstract

“…[ 3 ] However, it has been found that a certain enzyme that has been implicated in a range of neurological disorders may serve as a biomarker. [ 4–6 ]…”

Section: Introductionmentioning

confidence: 99%

Sulfonyl thioureas with a benzo[d]thiazole ring as dual acetylcholinesterase/butyrylcholinesterase and human monoamine oxidase A and B inhibitors: An in vitro and in silico study

Dinh Thanh,

Son Hai,

Ngoc Toan

et al. 2024

Archiv der Pharmazie

View full text Add to dashboard Cite

A series of sulfonyl thioureas 6a–q containing a benzo[d]thiazole ring with an ester functional group was synthesized from corresponding substituted 2‐aminobenzo[d]thiazoles 3a–q and p‐toluenesulfonyl isothiocyanate. They had remarkable inhibitory activity against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), monoamine oxidase (MAO)‐A, and MAO‐B. Among thioureas, several compounds had notable activity in the order of 6k > 6 h > 6c (AChE), 6j > 6g > 6k (BChE), 6k > 6g > 6f (MAO‐A), and 6i > 6k > 6h (MAO‐B). Compound 6k was an inhibitor of interest due to its potent or good activity against all studied enzymes, with IC50 values of 0.027 ± 0.008 μM (AChE), 0.043 ± 0.004 μM (BChE), 0.353 ± 0.01 μM (MAO‐A), and 0.716 ± 0.02 μM (MAO‐B). This inhibitory capacity was comparable to that of the reference drugs for each enzyme. Kinetic studies of two compounds with potential activity, 6k (against AChE) and 6j (against BChE), had shown that both 6k and 6j followed competitive‐type enzyme inhibition, with Ki constants of 24.49 and 12.16 nM, respectively. Induced fit docking studies for enzymes 4EY7, 7BO4, 2BXR, and 2BYB showed active interactions between sulfonyl thioureas of benzo[d]thiazoles and the residues in the active pocket with ligands 6k, 6i, and 6j, respectively. The stability of the ligand–protein complexes while each ligand entered the active site of each enzyme (4EY7, 7BO4, 2BXR, or 2BYB) was confirmed by molecular dynamics simulations.

show abstract

Recent progress in plasmonic nanoparticle‐based biomarker detection and cytometry for the study of central nervous system disorders

Cited by 7 publications

References 104 publications

Recent Advancements in Phyto Component Based Nanocarriers for Improved Treatment of Brain Disorders

Recent Advancements in Phyto Component Based Nanocarriers for Improved Treatment of Brain Disorders

Recent Progress on Biosensors for the Early Detection of Neurological Disorders.

Sulfonyl thioureas with a benzo[d]thiazole ring as dual acetylcholinesterase/butyrylcholinesterase and human monoamine oxidase A and B inhibitors: An in vitro and in silico study

Contact Info

Product

Resources

About